open access

Vol 11, No 6 (2015)
Research paper
Published online: 2016-03-08
Get Citation

Fiducial markers in the treatment of prostate cancer: technique and short term observation

Teresa Gawlik-Jakubczak, Marcin Matuszewski
Oncol Clin Pract 2015;11(6):295-299.

open access

Vol 11, No 6 (2015)
ORIGINAL ARTICLES
Published online: 2016-03-08

Abstract

Introduction: Prostate cancer (PC) is one of the most common cancers in the elderly population. The incidence is constantly growing. Radiotherapy for PC is rapidly evolving, which contributes to better cancer control. The escalation of RT dose requires better target localisation in order to avoid RT complications. Fiducial markers are improvements widely used for better accuracy of radiation.

Material and method: We implanted gold markers to 56 patients with confirmed PC between January and August 2014. After the procedure we controlled complication rate and proper localisation of the markers.

Results: No serious complication occurred. We observed a few cases of epididymitis, dysuria, and blood trace in urine. Four patients lost one seed.

Conclusions: Implantation of fiducial markers is simple and save ambulatory procedure and improves the results of radical radiotherapy in PC due to exact positioning.

Abstract

Introduction: Prostate cancer (PC) is one of the most common cancers in the elderly population. The incidence is constantly growing. Radiotherapy for PC is rapidly evolving, which contributes to better cancer control. The escalation of RT dose requires better target localisation in order to avoid RT complications. Fiducial markers are improvements widely used for better accuracy of radiation.

Material and method: We implanted gold markers to 56 patients with confirmed PC between January and August 2014. After the procedure we controlled complication rate and proper localisation of the markers.

Results: No serious complication occurred. We observed a few cases of epididymitis, dysuria, and blood trace in urine. Four patients lost one seed.

Conclusions: Implantation of fiducial markers is simple and save ambulatory procedure and improves the results of radical radiotherapy in PC due to exact positioning.

Get Citation

Keywords

prostate cancer, radiotherapy, markers

About this article
Title

Fiducial markers in the treatment of prostate cancer: technique and short term observation

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 6 (2015)

Article type

Research paper

Pages

295-299

Published online

2016-03-08

Bibliographic record

Oncol Clin Pract 2015;11(6):295-299.

Keywords

prostate cancer
radiotherapy
markers

Authors

Teresa Gawlik-Jakubczak
Marcin Matuszewski

References (17)
  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69–90.
  2. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie. http://onkologia.org.pl/raporty/ /02/06/2015.
  3. Dearnaley D, Sydes M, Graham J, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. The Lancet Oncology. 2007; 8(6): 475–487.
  4. Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24(13): 1990–1996.
  5. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294(10): 1233–1239.
  6. Beard CJ, Kijewski P, Bussiere M, et al. Analysis of prostate and seminal vesicle motion: Implications for treatment planning. Int J Radiat Oncol Biol Phys. 1997; 38: 73–81.
  7. Melian E, Mageras G, Fuks Z, et al. Variation in prostate position quantitation and implications for three-dimensional conformal treatment planning. International Journal of Radiation Oncology*Biology*Physics. 1997; 38(1): 73–81.
  8. Ng M, Brown E, Williams A, et al. Fiducial markers and spacers in prostate radiotherapy: current applications. BJU Int. 2014; Suppl 2: 13–20.
  9. Litzenberg D, Dawson LA, Sandler H, et al. Daily prostate targeting using implanted radiopaque markers. Int J Radiat Oncol Biol Phys. 2002; 52(3): 699–703.
  10. Vigneault E, Pouliot J, Laverdière J, et al. Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: a clinical study. Int J Radiat Oncol Biol Phys. 1997; 37(1): 205–212.
  11. Crook JM, Raymond Y, Salhani D, et al. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995; 37(1): 35–42.
  12. Linden RA, Weiner PR, Gomella LG, et al. Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology. 2009; 73(4): 881–886.
  13. Poggi MM, Gant DA, Sewchand W, et al. Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys. 2003; 56(5): 1248–1251.
  14. Brown S, Lehman M, Ferrari-Anderson J, et al. Assessment of prostatic fiducial marker introduction: patient morbidity, staff satisfaction and improved treatment field placement. J Med Imaging Radiat Oncol. 2011; 55(4): 417–424.
  15. Tang CI, Sethukavalan P, Cheung P, et al. A prospective study on pain score with transperineal prostatic gold seed fiducial implantation under local anesthetic alone. Can Urol Assoc J. 2013; 7(3-4): 202–206.
  16. Munoz F, Fiandra C, Franco P, et al. Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiol Med. 2012; 117(6): 1057–1070.
  17. Gates LL, Gladstone DJ, Kasibhatla MS, et al. Stability of serrated gold coil markers in prostate localization. J Appl Clin Med Phys. 2011; 12(3): 3453–3456.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl